References

1.       Aaltonen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltomäki P, et al. (1998). Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 338(21):1481–7. PMID:9593786

2.       Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, et al. (1999). Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 81(2):214–8. PMID:10188721

3.       Abati AD, Kimmel M, Rosen PP (1990). Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am J Clin Pathol. 94(4):371–7. PMID:2171320

4.       Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, et al. (2005). High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 116(3):340–50. PMID:15818618

5.       Abdeen A, Chou AJ, Healey JH, Khanna C, Osborne TS, Hewitt SM, et al. (2009). Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer. 115(22):5243–50. PMID:19670450

6.       Abdel-Fatah TM, Powe DG, Hodi Z, Lee AH, Reis-Filho JS, Ellis IO (2007). High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol. 31(3):417–26. PMID:17325484

7.       Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, Lee AH, Ellis IO (2008). Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol. 32(4):513–23. PMID:18223478

8.       Aboumrad MH, Horn RC Jr, Fine G (1963). Lipid-secreting mammary carcinoma. Report of a case associated with Paget’s disease of the nipple. Cancer. 16:521–5. PMID:14010714

9.       Abraham SC, Reynolds C, Lee JH, Montgomery EA, Baisden BL, Krasinskas AM, et al. (2002). Fibromatosis of the breast and mutations involving the APC/beta-catenin pathway. Hum Pathol. 33(1):39–46. PMID:11823972

10.     Abramowitz MC, Li T, Morrow M, Sigurdson ER, Anderson P, Nicolaou N, et al. (2009). Dermal lymphatic invasion and inflammatory breast cancer are independent predictors of outcome after postmastectomy radiation. Am J Clin Oncol. 32(1):30–3. PMID:19194121

11.     Abrial SC, Penault-Llorca F, Delva R, Bougnoux P, Leduc B, Mouret-Reynier MA, et al. (2005). High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 94(3):255–63. PMID:16267618

12.     Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, et al. (1996). hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A. 93(24):13629–34. PMID:8942985

13.     Achatz MI, Hainaut P, Ashton-Prolla P (2009). Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol. 10(9):920–5. PMID:19717094

14.     Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ (2001). Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol. 115(1):85–98. PMID:11190811

14A.     Acs G, Simpson JF, Bleiweiss IJ, Hugh J, Reynolds C, Olson S, et al. (2003). Microglandular adenosis with transition into adenoid cystic carcinoma of the breast. Am J Surg Pathol. 27(8):1052–60. PMID:12883237

15.     Adami HO, Hansen J, Jung B, Lindgren A, Rimsten A (1981). Bilateral carcinoma of the breast. Epidemiology and histopathology. Acta Radiol Oncol. 20(5):305–9. PMID:6278849

15A.     Adem C, Reynolds C, Adlakha H, Roche PC, Nascimento AG (2002). Wide spectrum screening keratin as a marker of metaplastic spindle cell carcinoma of the breast: an immunohistochemical study of 24 patients. Histopathology. 40(6):556–62. PMID:12047767

15B.     Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F, et al. (2007). Integrated profiling of basal and luminal breast cancers. Cancer Res. 67(24):11565–75. PMID:18089785

16.     Adem C, Reynolds C, Ingle JN, Nascimento AG (2004). Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer. 91(2):237–41. PMID:15187996

17.     Adeniran A, Al-Ahmadie H, Mahoney MC, Robinson-Smith TM (2004). Granular cell tumor of the breast: a series of 17 cases and review of the literature. Breast J. 10(6):528–31. PMID:15569210

18.     Adrada B, Arribas E, Gilcrease M, Yang WT (2009). Invasive micropapillary carcinoma of the breast: mammographic, sonographic, and MRI features. AJR Am J Roentgenol. 193(1):W58-63. PMID:19542384

19.     Agrawal A, Ayantunde AA, Rampaul R, Robertson JF (2007). Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 103(1):11–21. PMID:17033919

20.     Ahmed AA, Heller DS (2000). Malignant adenomyoepithelioma of the breast with malignant proliferation of epithelial and myoepithelial elements: a case report and review of the literature. Arch Pathol Lab Med. 124(4):632–6. PMID:10747327

20A.     Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, et al.; SEARCH; GENICA Consortium; kConFab; Australian Ovarian Cancer Study Group (2009). Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet. 41(5):585–90. PMID:19330027

21.     Aida Y, Takeuchi E, Shinagawa T, Tadokoro M, Inoue S, Omata Y, et al. (1993). Fine needle aspiration cytology of lipid-secreting carcinoma of the breast. A case report. Acta Cytol. 37(4):547–51. PMID:8328251

22.     Aktepe F, Kapucuoğlu N, Pak I (1996). The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology. 29(1):63–7. PMID:8818696

23.     Al Sarakbi W, Worku D, Escobar PF, Mokbel K (2006). Breast papillomas: current management with a focus on a new diagnostic and therapeutic modality. Int Semin Surg Oncol. 3:1. [Abstract] PMID:16417642

24.     Alagaratnam TT, Ng WF, Leung EY (1995). Giant fibroadenomas of the breast in an oriental community. J R Coll Surg Edinb. 40(3):161–2. PMID:7616467

25.     Albonico G, Querzoli P, Ferretti S, Rinaldi R, Nenci I (1998). Biological profile of in situ breast cancer investigated by immunohistochemical technique. Cancer Detect Prev. 22(4):313–8. PMID:9674874

26.     Albores-Saavedra J, Heard SC, McLaren B, Kamino H, Witkiewicz AK (2005). Cylindroma (dermal analog tumor) of the breast: a comparison with cylindroma of the skin and adenoid cystic carcinoma of the breast. Am J Clin Pathol. 123(6):866–73. PMID:15899777

27.     Alexander DD, Morimoto LM, Mink PJ, Cushing CA (2010). A review and meta-analysis of red and processed meat consumption and breast cancer. Nutr Res Rev. 23(2):349–65. PMID:21110906

28.     Ali E, Athanasopoulos PG, Forouhi P, Malata CM (2011). Cowden syndrome and reconstructive breast surgery: case reports and review of the literature. J Plast Reconstr Aesthet Surg. 64(4):545–9. PMID:20627761

29.     Ali S, Teichberg S, DeRisi DC, Urmacher C (1994). Giant myofibroblastoma of the male breast. Am J Surg Pathol. 18(11):1170–6. PMID:7943539

30.     Ali-Fehmi R, Carolin K, Wallis T, Visscher DW (2003). Clinicopathologic analysis of breast lesions associated with multiple papillomas. Hum Pathol. 34(3):234–9. PMID:12673557

31.     Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, et al. (2010). Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 42(5):454–8. PMID:20400965

32.     Allred DC (2010). Biological features of human premalignant breast disease and the progression to cancer. In: Harris JR, Lippman ME, Morrow M, Osbourne CK, editors. Diseases of the breast. 4th ed. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins; pp. 323–34.

33.     Allred DC (2010). Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer. Mod Pathol. 23 Suppl 2:S52–9. PMID:20436503

34.     Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. (2012). Adjuvant tamoxifen reduces subsequent breast cancer in women with hormone receptor-positive DCIS: a study based on NSABP protocol B- 24. J Clin Oncol. 30:1268–73 PMID:22393101

34A.     Allred DC, Briant J, Paik S, Fisher E, Julian T, Margolese R, et al. (2002). Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from the NSABP Protocol B-24. Breast Cancer Res Treat. 76 Suppl 1:A30.

34B.     Allred DC, Brown P, Medina D (2004). The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 6(6):240–5. PMID:15535853

35.     Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, et al. (2009). NCCN Task Force Report: Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw. 7 Suppl 6:S1–21, quiz S22–3. PMID:19755043

36.     Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. (2008). Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res. 14(2):370–8. PMID:18223211

37.     Alpaugh ML, Tomlinson JS, Ye Y, Barsky SH (2002). Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol. 161(2):619–28. PMID:12163386

38.     Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. (Cancer Statistics Review SEER, editor). Feuer.E.J., Stinchcomb DG, Edwards BK. Bethesda (MD): National Cancer Institute; pp. 1975–2007. Available from: http://seer.cancer.gov/csr/1975_2007/

39.     Alva S, Shetty-Alva N (1999). An update of tumor metastasis to the breast data. Arch Surg. 134(4):450. PMID:10199322

40.     Alvarado Cabrero I, Carrera Alvarez M, Pérez Montiel D, Tavassoli FA (2003). Metastases to the breast. Eur J Surg Oncol. 29(10):854–5. PMID:14624777

41.     Alvarez S, Diaz-Uriarte R, Osorio A, Barroso A, Melchor L, Paz MF, et al. (2005). A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation. Clin Cancer Res. 11(3):1146–53. PMID:15709182

42.     Amichetti M, Perani B, Boi S (1990). Metastases to the breast from extramammary malignancies. Oncology. 47(3):257–60. PMID:2342767

43.     Amir H, Hirji KF (1992). Carcinoma of the male breast in Tanzania. J Natl Med Assoc. 84(4):337–40. PMID:1507248

44.     Andersen JA, Gram JB (1982). Male breast at autopsy. Acta Pathol Microbiol Immunol Scand A. 90(3):191–7. PMID:6285667

45.     Andersen JA, Vendelboe ML (1981). Cytoplasmic mucous globules in lobular carcinoma in situ. Diagnosis and prognosis. Am J Surg Pathol. 5(3):251–5. PMID:6165250

46.     Anderson E (2002). The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res. 4(5):197–201. PMID:12223124

47.     Anderson JA (1974). Lobular carcinoma in situ. A histological study of 52 cases. Acta Pathol Microbiol Scand A. 82(6):735–41. PMID:4141215

48.     Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006). Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev. 15(10):1899–905. PMID:17035397

49.     Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, et al. (2006). Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol. 24(21):3361–6. PMID:16801631

50.     Ang MK, Ooi AS, Thike AA, Tan P, Zhang Z, Dykema K, et al. (2011). Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression. Breast Cancer Res Treat. 129(2):319–29. PMID:20945089

51.     Angèle S, Jones C, Reis Filho JS, Fulford LG, Treilleux I, Lakhani SR, et al. (2004). Expression of ATM, p53, and the MRE11-Rad50-NBS1 complex in myoepithelial cells from benign and malignant proliferations of the breast. J Clin Pathol. 57(11):1179–84. PMID:15509680

52.     Angèle S, Jones C, Reis Filho JS, Fulford LG, Treilleux I, Lakhani SR, et al. (2004). Expression of ATM, p53, and the MRE11-Rad50-NBS1 complex in myoepithelial cells from benign and malignant proliferations of the breast. J Clin Pathol. 57(11):1179–84. PMID:15509680

53.     Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, et al. (2009). KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 69(18):7175–9. PMID:19723655

53A.     Ansquer Y, Delaney S, Santulli P, Salomon L, Carbonne B, Salmon R (2010). Risk of invasive breast cancer after lobular intra-epithelial neoplasia: review of the literature. Eur J Surg Oncol. 36(7):604–9. PMID:20541352

54.     Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 72(5):1117–30. PMID:12677558

55.     Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, et al.; Ontario Cancer Genetics Network; SWE-BRCA; HEBON; EMBRACE; GEMO; GEMO; Breast Cancer Family Registry; kConFab; CIMBA (2010). Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 70(23):9742–54. PMID:21118973

56.     Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. (2008). The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 98(8):1457–66. PMID:18349832

57.     Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, et al. (2008). Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet. 45(7):425–31. PMID:18413374

58.     Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al. (2002). A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 86(1):76–83. PMID:11857015

59.     Antoniou AC, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. (2005). Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet. 42(7):602–3. PMID:15994883

60.     Antoniou AC, Pharoah PP, Smith P, Easton DF (2004). The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer. 91(8):1580–90. PMID:15381934

61.     Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, et al.; EMBRACE; GENEPSO; GEO-HEBON (2009). Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 18(2):601–10. PMID:19190154

62.     Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, et al.; Kathleen Cuningham Consortium for Research into Familial Breast Cancer; OCGN; Swedish BRCA1 and BRCA2 study collaborators; DNA-HEBON collaborators; EMBRACE; GEMO; CIMBA (2008). Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet. 82(4):937–48. PMID:18355772

63.     Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, et al.; EMBRACE; GEMO Study Collaborators; HEBON; kConFab; SWE-BRCA; MOD SQUAD; GENICA (2010). A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet. 42(10):885–92. PMID:20852631

63A.     Aparicio SA, Huntsman DG (2010). Does massively parallel DNA resequencing signify the end of histopathology as we know it? J Pathol. 220(2):307–15. PMID:19921711

64.     Arbabi L, Warhol MJ (1982). Pleomorphic liposarcoma following radiotherapy for breast carcinoma. Cancer. 49(5):878–80. PMID:7059926

65.     Arber DA, Simpson JF, Weiss LM, Rappaport H (1994). Non-Hodgkin’s lymphoma involving the breast. Am J Surg Pathol. 18(3):288–95. PMID:8116797

66.     Arce C, Cortes-Padilla D, Huntsman DG, Miller MA, Dueñnas-Gonzalez A, Alvarado A, et al. (2005). Secretory carcinoma of the breast containing the ETV6-NTRK3 fusion gene in a male: case report and review of the literature. World J Surg Oncol. 3:35. PMID:15963235

67.     Arias-Stella J Jr, Rosen PP (1988). Hemangiopericytoma of the breast. Mod Pathol. 1(2):98–103. PMID:3237697

68.     Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, et al. (1998). The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer. 83(11):2335–45. PMID:9840533

69.     Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al. (1999). Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 59(8):2011–7. PMID:10213514

70.     Arnedos M, Nerurkar A, Osin P, A’Hern R, Smith IE, Dowsett M (2009). Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). Ann Oncol. 20(12):1948–52. PMID:19570962

71.     Arnes JB, Brunet JS, Stefansson I, Bégin LR, Wong N, Chappuis PO, et al. (2005). Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 11(11):4003–11. PMID:15930334

72.     Aroner SA, Collins LC, Schnitt SJ, Connolly JL, Colditz GA, Tamimi RM (2010). Columnar cell lesions and subsequent breast cancer risk: a nested case-control study. Breast Cancer Res. 12(4):R61. PMID:20691043

73.     Arpino G, Bardou VJ, Clark GM, Elledge RM (2004). Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 6(3):R149–56. PMID:15084238

74.     Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al.; National Surgical Adjuvant Breast, Bowel Project (2010). Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 102(2):111–8. PMID:20648579

75.     Ashikari R, Huvos AG, Urban JA, Robbins GF (1973). Infiltrating lobular carcinoma of the breast. Cancer. 31(1):110–6. PMID:4345605

76.     Asioli S, Marucci G, Ficarra G, Stephens M, Foschini MP, Ellis IO, et al. (2006). Polymorphous adenocarcinoma of the breast. Report of three cases. Virchows Arch. 448(1):29–34. PMID:16220292

76A.     Asoglu O, Ugurlu MM, Blanchard K, Grant CS, Reynolds C, Cha SS, et al. (2004). Risk factors for recurrence and death after primary surgical treatment of malignant phyllodes tumors. Ann Surg Oncol. 11(11):1011–7. PMID:15525831

77.     Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. (2008). Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 26(26):4282–8. PMID:18779615

78.     Aubele MM, Cummings MC, Mattis AE, Zitzelsberger HF, Walch AK, Kremer M, et al. (2000). Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer. Diagn Mol Pathol. 9(1):14–9. PMID:10718208

79.     Aulmann S, Elsawaf Z, Penzel R, Schirmacher P, Sinn HP (2009). Invasive tubular carcinoma of the breast frequently is clonally related to flat epithelial atypia and low-grade ductal carcinoma in situ. Am J Surg Pathol. 33(11):1646–53. PMID:19675453

80.     Austin RM, Dupree WB (1986). Liposarcoma of the breast: a clinicopathologic study of 20 cases. Hum Pathol. 17(9):906–13. PMID:3019868

81.     Aydin O, Cinel L, Egilmez R, Ocal K, Ozer C (2001). Adenomyoepithelioma of the breast. Diagn Cytopathol. 25(3):194–6. PMID:11536445

82.     Azoulay S, Laé M, Fréneaux P, Merle S, Al Ghuzlan A, Chnecker C, et al. (2005). KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol. 18(12):1623–31. PMID:16258515

83.     Azumi N, Battifora H (1987). The cellular composition of adenoid cystic carcinoma. An immunohistochemical study. Cancer. 60(7):1589–98. PMID:2441847

84.     Azzopardi JG, Ahmed A, Millis RR (1979). Problems in breast pathology. Major problems in pathology. Phildelphia: Saunders.

85.     Azzopardi JG, Eusebi V (1977). Melanocyte colonization and pigmentation of breast carcinoma. Histopathology. 1(1):21–30. PMID:615831

86.     Azzopardi JG, Salm R (1984). Ductal adenoma of the breast: a lesion which can mimic carcinoma. J Pathol. 144(1):15–23. PMID:6090627

87.     Bachmeier BE, Nerlich AG, Mirisola V, Jochum M, Pfeffer U (2008). Lineage infidelity and expression of melanocytic markers in human breast cancer. Int J Oncol. 33(5):1011–5. PMID:18949364

88.     Baddoura FK, Judd RL (1990). Apocrine adenoma of the breast: report of a case with investigation of lectin binding patterns in apocrine breast lesions. Mod Pathol. 3(3):373–6. PMID:2362943

89.     Badve S, Sloane JP (1995). Pseudoangiomatous hyperplasia of male breast. Histopathology. 26(5):463–6. PMID:7544764

90.     Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, et al.; Dutch Lynch Syndrome Study Group (2010). Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 102(3):193–201. PMID:20028993

91.     Bahrami A, Resetkova E, Ro JY, Ibañez JD, Ayala AG (2007). Primary osteosarcoma of the breast: report of 2 cases. Arch Pathol Lab Med. 131(5):792–5. PMID:17488168

92.     Baker TP, Lenert JT, Parker J, Kemp B, Kushwaha A, Evans G, et al. (2001). Lactating adenoma: a diagnosis of exclusion. Breast J. 7(5):354–7. PMID:11906446

93.     Ball S, Arolker M, Purushotham AD (2001). Breast cancer, Cowden disease and PTEN-MATCHS syndrome. Eur J Surg Oncol. 27(6):604–6. PMID:11520097

94.     Ballance WA, Ro JY, el-Naggar AK, Grignon DJ, Ayala AG, Romsdahl MG (1990). Pleomorphic adenoma (benign mixed tumor) of the breast. An immunohistochemical, flow cytometric, and ultrastructural study and review of the literature. Am J Clin Pathol. 93(6):795–801. PMID:2161180

95.     Balleine RL, Murali R, Bilous AM, Farshid G, Waring P, Provan P, et al.; kConFab Investigators (2006). Histopathological features of breast cancer in carriers of ATM gene variants. Histopathology. 49(5):523–32. PMID:17064299

96.     Bane AL, Beck JC, Bleiweiss I, Buys SS, Catalano E, Daly MB, et al. (2007). BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 31(1):121–8. PMID:17197928

97.     Bane AL, Pinnaduwage D, Colby S, Reedijk M, Egan SE, Bull SB, et al. (2009). Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat. 117(1):183–91. PMID:18563556

98.     Bane AL, Tjan S, Parkes RK, Andrulis I, O’Malley FP (2005). Invasive lobular carcinoma: to grade or not to grade. Mod Pathol. 18(5):621–8. PMID:15605082

99.     Banerjee SS, Harris M (2000). Morphological and immunophenotypic variations in malignant melanoma. Histopathology. 36(5):387–402. PMID:10792480

99A.     Banev SG, Filipovski VA (2006). Chondrolipoma of the breast–case report and a review of literature. Breast. 15(3):425–6. PMID:16131470

100.   Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, et al. (2010). Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res. 12(4):R63. PMID:20712882

101.   Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, et al. (2001). p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol. 25(8):1054–60. PMID:11474290

102.   Barbosa ML, Ribeiro EM, Silva GF, Maciel ME, Lima RS, Cavalli LR, et al. (2004). Cytogenetic findings in phyllodes tumor and fibroadenomas of the breast. Cancer Genet Cytogenet. 154(2):156–9. PMID:15474152

103.   Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003). Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 21(10):1973–9. PMID:12743151

104.   Barkley CR, Ligibel JA, Wong JS, Lipsitz S, Smith BL, Golshan M (2008). Mucinous breast carcinoma: a large contemporary series. Am J Surg. 196(4):549–51. PMID:18809061

105.   Barnes L, Pietruszka M (1978). Rhabdomyosarcoma arising within a cystosarcoma phyllodes. Case report and review of the literature. Am J Surg Pathol. 2(4):423–9. PMID:216277

105A.   Barnes PJ, Boutilier R, Chiasson D, Rayson D (2005). Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat. 91(2):173–8. PMID:15868445

106.   Barrio AV, Clark BD, Goldberg JI, Hoque LW, Bernik SF, Flynn LW, et al. (2007). Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 14(10):2961–70. PMID:17562113

107.   Bartlett JM, Ibrahim M, Jasani B, Morgan JM, Ellis I, Kay E, et al. (2007). External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol. 60(7):816–9. PMID:16963466

108.   Basham VM, Lipscombe JM, Ward JM, Gayther SA, Ponder BA, Easton DF, et al. (2002). BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res. 4(1):R2. [Abstract] PMID:11879560

109.   Bässler R, Katzer B (1992). Histopathology of myoepithelial (basocellular) hyperplasias in adenosis and epitheliosis of the breast demonstrated by the reactivity of cytokeratins and S100 protein. An analysis of heterogenic cell proliferations in 90 cases of benign and malignant breast diseases. Virchows Arch A Pathol Anat Histopathol. 421(5):435–42. PMID:1280883

110.   Basu SK, Schwartz C, Fisher SG, Hudson MM, Tarbell N, Muhs A, et al. (2008). Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 72(1):34–40. PMID:18722264

111.   Beck AH, Lee CH, Witten DM, Gleason BC, Edris B, Espinosa I, et al. (2010). Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene. 29(6):845–54. PMID:19901961

112.   Bedard PL, Cardoso F, Piccart-Gebhart MJ (2009). Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia. 14(1):55–66. PMID:19259796

113.   Begum SM, Jara-Lazaro AR, Thike AA, Tse GM, Wong JS, Ho JT, et al. (2009). Mucin extravasation in breast core biopsies–clinical significance and outcome correlation. Histopathology. 55(5):609–17. PMID:19912367

114.   Bellezza G, Lombardi T, Panzarola P, Sidoni A, Cavaliere A, Giansanti M (2007). Schwannoma of the breast: a case report and review of the literature. Tumori. 93(3):308–11. PMID:17679472

115.   Bennett KL, Mester J, Eng C (2010). Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA. 304(24):2724–31. PMID:21177507

116.   Bentz JS, Yassa N, Clayton F (1998). Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod Pathol. 11(9):814–22. PMID:9758360

117.   Beral V; Million Women Study Collaborators (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 362(9382):419–27. PMID:12927427

118.   Beral V, Reeves G, Bull D, Green J; Million Women Study Collaborators (2011). Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 103(4):296–305. PMID:21278356

118A.   Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lonning PE, et al. (2006). Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 45(11):1033–40. PMID:16897746

119.   Bergstraesser LM, Srinivasan G, Jones JC, Stahl S, Weitzman SA (1995). Expression of hemidesmosomes and component proteins is lost by invasive breast cancer cells. Am J Pathol. 147(6):1823–39. PMID:7495306

120.   Bernstein JL, Haile RW, Stovall M, Boice JD Jr, Shore RE, Langholz B, et al.; WECARE Study Collaborative Group (2010). Radiation exposure, the ATM Gene, and contralateral breast cancer in the women’s environmental cancer and radiation epidemiology study. J Natl Cancer Inst. 102(7):475–83. PMID:20305132

121.   Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, et al. (2006). Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066–6T>G (IVS10–6T>G) from the Breast Cancer Family Registry. Hum Mutat. 27(11):1122–8. PMID:16958054

122.   Bernstein L (2002). Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 7(1):3–15. PMID:12160084

123.   Bernstein L, Patel AV, Ursin G, Sullivan-Halley J, Press MF, Deapen D, et al. (2005). Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst. 97(22):1671–9. PMID:16288120

124.   Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, et al. (2002). BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 20(11):2701–12. PMID:12039933

125.   Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, et al.; Women’s Environment, Cancer and Radiation Epidemiology Study Collaborative Group (2008). Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women’s Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 100(1):32–40. PMID:18159070

126.   Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adélaïde J, et al. (2006). Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 66(9):4636–44. PMID:16651414

126A.   Bertucci F, Orsetti B, Nègre V, Finetti P, Rougé C, Ahomadegbe JC, et al. (2008). Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene. 27(40):5359–72. PMID:18490921

127.   Berx G, Becker KF, Höfler H, van Roy F (1998). Mutations of the human E-cadherin (CDH1) gene. Hum Mutat. 12(4):226–37. PMID:9744472

128.   Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M, Cornelisse C, et al. (1995). E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 14(24):6107–15. PMID:8557030

129.   Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, et al. (1996). E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 13(9):1919–25. PMID:8934538

130.   Beute BJ, Kalisher L, Hutter RV (1991). Lobular carcinoma in situ of the breast: clinical, pathologic, and mammographic features. AJR Am J Roentgenol. 157(2):257–65. PMID:1853802

131.   Bezić J, Forempoher G, Poljicanin A, Gunjaca G (2007). Apocrine adenoma of the breast coexistent with invasive carcinoma. Pathol Res Pract. 203(11):809–12. PMID:17936522

132.   Bhargava R, Beriwal S, Striebel JM, Dabbs DJ (2010). Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl Immunohistochem Mol Morphol. 18(2):113–8. PMID:19801938

133.   Bhargava R, Dabbs DJ (2007). Use of immunohistochemistry in diagnosis of breast epithelial lesions. Adv Anat Pathol. 14(2):93–107. PMID:17471116

134.   Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. (1996). Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med. 334(12):745–51. PMID:8592547

135.   Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, Ricci F, Weber K, Furlong MA, et al. (2005). Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 29(5):653–9. PMID:15832090

136.   Bianchi S, Vezzosi V (2008). Microinvasive carcinoma of the breast. Pathol Oncol Res. 14(2):105–11. PMID:18493870

137.   Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al.; EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group (2006). Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853–a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 24(21):3381–7. PMID:16801628

138.   Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, et al. (2001). Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 19(8):2263–71. PMID:11304780

139.   Billings SD, McKenney JK, Folpe AL, Hardacre MC, Weiss SW (2004). Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol. 28(6):781–8. PMID:15166670

140.   Bilous M (2010). Breast core needle biopsy: issues and controversies. Mod Pathol. 23 Suppl 2:S36–45. PMID:20436501

141.   Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, et al. (2001). Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 20(34):4621–8. PMID:11498785

142.   Birch JM, Blair V, Kelsey AM, Evans DG, Harris M, Tricker KJ, et al. (1998). Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 17(9):1061–8. PMID:9764816

143.   Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, et al. (1994). Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 54(5):1298–304. PMID:8118819

144.   Birdsall SH, Shipley JM, Summersgill BM, Black AJ, Jackson P, Kissin MW, et al. (1995). Cytogenetic findings in a case of nodular fasciitis of the breast. Cancer Genet Cytogenet. 81(2):166–8. PMID:7621414

145.   Black J, Metcalf C, Wylie EJ (1996). Ultrasonography of breast hamartomas. Australas Radiol. 40(4):412–5. PMID:8996902

146.   Blamey RW, Pinder SE, Ball GR, Ellis IO, Elston CW, Mitchell MJ, et al. (2007). Reading the prognosis of the individual with breast cancer. Eur J Cancer. 43(10):1545–7. PMID:17320376

147.   Blanchard DK, Reynolds CA, Grant CS, Donohue JH (2003). Primary nonphylloides breast sarcomas. Am J Surg. 186(4):359–61. PMID:14553850

148.   Blanco A, Graña B, Fachal L, Santamariña M, Cameselle-Teijeiro J, Ruíz-Ponte C, et al. (2010). Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN. Clin Genet. 77(2):193–6. PMID:19930417

149.   Bleicher RJ, O’Sullivan MJ, Ciocca V, Ciocca RM, Perkins LA, Ross E, et al. (2008). A prospective feasibility trial to determine the significance of the sentinel node gradient in breast cancer: a predictor of nodal metastasis location. Cancer. 113(11):3100–7. PMID:18973177

149A.   Bleiweiss IJ, Nagi CS, Jaffer S (2006). Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol. 24(13):2013–8. PMID:16606970

150.   Bloch KE, Marincek B, Amann FW, Russi EW (1991). Pulmonary hypertension five years after left pneumonectomy for adenoid cystic carcinoma. Chest. 99(4):1018–9. PMID:1849064

151.   Bloom HJ, Richardson WW (1957). Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 11(3):359–77. PMID:13499785

152.   Bluemke DA, Gatsonis CA, Chen MH, DeAngelis GA, DeBruhl N, Harms S, et al. (2004). Magnetic resonance imaging of the breast prior to biopsy. JAMA. 292(22):2735–42. PMID:15585733

153.   Bodian CA, Perzin KH, Lattes R, Hoffmann P (1993). Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications. Cancer. 71(12):3908–13. PMID:8508356

154.   Boecker W, Buerger H (2004). Usual and atypical ductal hyperplasia - members of the same family? Curr Diagn Pathol. 10:175–82.

155.   Boecker W, Moll R, Dervan P, Buerger H, Poremba C, Diallo RI, et al. (2002). Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol. 198(4):458–67. PMID:12434415

156.   Boffetta P, Couto E, Wichmann J, Ferrari P, Trichopoulos D, Bueno-de-Mesquita HB, et al. (2010). Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst. 102(8):529–37. PMID:20371762

157.   Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT (1992). Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 326(12):781–5. PMID:1538720

158.   Boland CR (2005). Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer. 4(3):211–8. PMID:16136380

159.   Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. (1998). A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58(22):5248–57. PMID:9823339

160.   Boldt V, Stacher E, Halbwedl I, Popper H, Hultschig C, Moinfar F, et al. (2010). Positioning of necrotic lobular intraepithelial neoplasias (LIN, grade 3) within the sequence of breast carcinoma progression. Genes Chromosomes Cancer. 49(5):463–70. PMID:20155841

161.   Bombonati A, Sgroi DC (2011). The molecular pathology of breast cancer progression. J Pathol. 223(2):307–17. PMID:21125683

162.   Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, et al. (1998). Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 16(1):93–100. PMID:9440728

163.   Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, et al. (1990). Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 82(19):1539–45. PMID:2402015

164.   Bonaventure P, Guo H, Tian B, Liu X, Bittner A, Roland B, et al. (2002). Nuclei and subnuclei gene expression profiling in mammalian brain. Brain Res. 943(1):38–47. PMID:12088837

165.   Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 119(5):591–602. PMID:15550242

166.   Bonnet M, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E, Contesso G, et al. (1999). Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst. 91(16):1376–81. PMID:10451442

167.   Bonnier P, Charpin C, Lejeune C, Romain S, Tubiana N, Beedassy B, et al. (1995). Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition? Int J Cancer. 62(4):382–5. PMID:7635562

168.   Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L (1995). Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol. 85(1):11–7. PMID:7800305

169.   Borgen PI, Wong GY, Vlamis V, Potter C, Hoffmann B, Kinne DW, et al. (1992). Current management of male breast cancer. A review of 104 cases. Ann Surg. 215(5):451–7, discussion 457–9. PMID:1319699

170.   Borst MJ, Ingold JA (1993). Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery. 114(4):637–41, discussion 641–2. PMID:8211676

171.   Botta G, Fessia L, Ghiringhello B (1982). Juvenile milk protein secreting carcinoma. Virchows Arch A Pathol Anat Histol. 395(2):145–52. PMID:7101723

172.   Boudova L, Kazakov DV, Sima R, Vanecek T, Torlakovic E, Lamovec J, et al. (2005). Cutaneous lymphoid hyperplasia and other lymphoid infiltrates of the breast nipple: a retrospective clinicopathologic study of fifty-six patients. Am J Dermatopathol. 27(5):375–86. PMID:16148405

173.   Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L, et al. (2006). Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 43(6):531–3. PMID:16258005

174.   Bougeard G, Sesboüé R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, et al.; French LFS working group (2008). Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet. 45(8):535–8. PMID:18511570

175.   Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, et al. (2006). Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 244(3):464–70. PMID:16926572

176.   Boulos FI, Dupont WD, Simpson JF, Schuyler PA, Sanders ME, Freudenthal ME, et al. (2008). Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study. Cancer. 113(9):2415–21. PMID:18816618

177.   Boussen H, Bouzaiene H, Ben Hassouna J, Dhiab T, Khomsi F, Benna F, et al. (2010). Inflammatory breast cancer in Tunisia: epidemiological and clinical trends. Cancer. 116(11) Suppl:2730–5. PMID:20503401

178.   Bowman K, Munoz A, Mahvi DM, Breslin TM (2007). Lobular neoplasia diagnosed at core biopsy does not mandate surgical excision. J Surg Res. 142(2):275–80. PMID:17662303

179.   Brain E, Garrino C, Misset JL, Carbonero IG, Itzhaki M, Cvitkovic E, et al. (1997). Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br J Cancer. 75(9):1360–7. PMID:9155059

180.   Bratthauer GL, Miettinen M, Tavassoli FA (2003). Cytokeratin immunoreactivity in lobular intraepithelial neoplasia. J Histochem Cytochem. 51(11):1527–31. PMID:14566024

181.   Breast Cancer Linkage Consortium (1997). Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 349(9064):1505–10. PMID:9167459

182.   Brenn T, Fletcher CD (2005). Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. Am J Surg Pathol. 29(8):983–96. PMID:16006792

183.   Brinkmann AO (2001). Molecular basis of androgen insensitivity. Mol Cell Endocrinol. 179(1-2):105–9. PMID:11420135

184.   Brinton LA, Carreon JD, Gierach GL, McGlynn KA, Gridley G (2010). Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat. 119(1):185–92. PMID:19330525

185.   Brinton LA, Richesson DA, Gierach GL, Lacey JV Jr, Park Y, Hollenbeck AR, et al. (2008). Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst. 100(20):1477–81. PMID:18840816

186.   Britton P, Duffy SW, Sinnatamby R, Wallis MG, Barter S, Gaskarth M, et al. (2009). One-stop diagnostic breast clinics: how often are breast cancers missed? Br J Cancer. 100(12):1873–8. PMID:19455145

187.   Britton PD (2011). Fine needle aspiration or core biopsy. Breast. 8:1–4.

188.   Brodie C, Provenzano E (2008). Vascular proliferations of the breast. Histopathology. 52(1):30–44. PMID:18171415

189.   Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, et al.; Genica Network; kConFab; AOCS (2011). Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 20(16):3289–303. PMID:21596841

190.   Broët P, de la Rochefordière A, Scholl SM, Fourquet A, Mosseri V, Durand JC, et al. (1995). Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 13(7):1578–83. PMID:7602346

191.   Brogi E (2004). Benign and malignant spindle cell lesions of the breast. Semin Diagn Pathol. 21(1):57–64. PMID:15074560

192.   Brogi E, Harris NL (1999). Lymphomas of the breast: pathology and clinical behavior. Semin Oncol. 26(3):357–64. PMID:10375092

193.   Brogi E, Oyama T, Koerner FC (2001). Atypical cystic lobules in patients with lobular neoplasia. Int J Surg Pathol. 9(3):201–6. PMID:11584316

194.   Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, et al. (2007). Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol. 25(25):3831–6. PMID:17635951

195.   Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, et al. (1994). Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 368(6468):258–61. PMID:8145827

196.   Brookes MJ, Bourke AG (2008). Radiological appearances of papillary breast lesions. Clin Radiol. 63(11):1265–73. PMID:18929044

197.   Brown AC, Audisio RA, Regitnig P (2011). Granular cell tumour of the breast. Surg Oncol. 20(2):97–105. PMID:20074934

198.   Brown AS, Hunt KK, Shen J, Huo L, Babiera GV, Ross MI, et al. (2010). Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer. 116(12):2878–83. PMID:20564394

199.   Brown DC, Theaker JM, Banks PM, Gatter KC, Mason DY (1987). Cytokeratin expression in smooth muscle and smooth muscle tumours. Histopathology. 11(5):477–86. PMID:2440790

200.   Brown V, Carty NJ (2005). A case of nodular fascitis of the breast and review of the literature. Breast. 14(5):384–7. PMID:16216741

201.   Brownstein MH, Wolf M, Bikowski JB (1978). Cowden’s disease: a cutaneous marker of breast cancer. Cancer 41: 2393–2398.

202.   Brustein S, Filippa DA, Kimmel M, Lieberman PH, Rosen PP (1987). Malignant lymphoma of the breast. A study of 53 patients. Ann Surg. 205(2):144–50.http://dx.doi.org/10.1097/00000658-198702000-00008 PMID:3545107

203.   Buchanan CL, Flynn LW, Murray MP, Darvishian F, Cranor ML, Fey JV, et al. (2008). Is pleomorphic lobular carcinoma really a distinct clinical entity? J Surg Oncol. 98(5):314–7.http://dx.doi.org/10.1002/jso.21121 PMID:18668643

204.   Buerger H, Mommers EC, Littmann R, Simon R, Diallo R, Poremba C, et al. (2001). Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol. 194(2):165–70. PMID:11400144

205.   Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, et al. (1999). Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol. 187(4):396–402. PMID:10398097

206.   Buerger H, Otterbach F, Simon R, Schäfer KL, Poremba C, Diallo R, et al. (1999). Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol. 189(4):521–6. PMID:10629552

207.   Buley ID, Gatter KC, Kelly PM, Heryet A, Millard PR (1988). Granular cell tumours revisited. An immunohistological and ultrastructural study. Histopathology. 12(3):263–74. PMID:2452781

208.   Bult P, Verwiel JM, Wobbes T, Kooy-Smits MM, Biert J, Holland R (2000). Malignant adenomyoepithelioma of the breast with metastasis in the thyroid gland 12 years after excision of the primary tumor. Case report and review of the literature. Virchows Arch. 436(2):158–66. PMID:10755607

209.   Bur ME, Zimarowski MJ, Schnitt SJ, Baker S, Lew R (1992). Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer. 69(5):1174–81. PMID:1739917

210.   Burga AM, Tavassoli FA (2003). Periductal stromal tumor: a rare lesion with low-grade sarcomatous behavior. Am J Surg Pathol. 27(3):343–8. PMID:12604890

211.   Butler RS, Venta LA, Wiley EL, Ellis RL, Dempsey PJ, Rubin E (1999). Sonographic evaluation of infiltrating lobular carcinoma. AJR Am J Roentgenol. 172(2):325–30. PMID:9930776

211A.   Buyse M, Loi S, van’t Veer L, Viale G, Delorenzi M, Glas AM, et al.; TRANSBIG Consortium (2006). Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 98(17):1183–92. PMID:16954471

212.   Buza N, Zekry N, Charpin C, Tavassoli FA (2010). Myoepithelial carcinoma of the breast: a clinicopathological and immunohistochemical study of 15 diagnostically challenging cases. Virchows Arch. 457(3):337–45. PMID:20658149

213.   Cabioglu N, Ozmen V, Kaya H, Tuzlali S, Igci A, Muslumanoglu M, et al. (2009). Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg. 208(1):67–74. PMID:19228505

214.   Cai RZ, Tan PH (2005). Adenomyoepithelioma of the breast with squamous and sebaceous metaplasia. Pathology. 37(6):557–9. PMID:16373236

215.   Calderaro J, Bayou EH, Castaigne D, Mathieu MC, Andreiuolo F, Suciu V, et al. (2010). Tubular adenoma of the breast with associated mucinous features: a cytological diagnostic trap. Cytopathology. 21(3):191–3. PMID:19456846

216.   Calderaro J, Espie M, Duclos J, Giachetti S, Wehrer D, Sandid W, et al. (2009). Breast intracystic papillary carcinoma: an update. Breast J. 15(6):639–44. PMID:19735389

217.   Caliskan M, Gatti G, Sosnovskikh I, Rotmensz N, Botteri E, Musmeci S, et al. (2008). Paget’s disease of the breast: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 112(3):513–21. PMID:18240020

218.   Camelo-Piragua SI, Habib C, Kanumuri P, Lago CE, Mason HS, Otis CN (2009). Mucoepidermoid carcinoma of the breast shares cytogenetic abnormality with mucoepidermoid carcinoma of the salivary gland: a case report with molecular analysis and review of the literature. Hum Pathol. 40(6):887–92. PMID:19200580

219.   Capella C, Eusebi V, Mann B, Azzopardi JG (1980). Endocrine differentiation in mucoid carcinoma of the breast. Histopathology. 4(6):613–30. PMID:6254868

220.   Capella C, Usellini L, Papotti M, Macrì L, Finzi G, Eusebi V, et al. (1990). Ultrastructural features of neuroendocrine differentiated carcinomas of the breast. Ultrastruct Pathol. 14(4):321–34. PMID:2200185

221.   Carey LA, Metzger R, Dees EC, Collichio F, Sartor CI, Ollila DW, et al. (2005). American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. J Natl Cancer Inst. 97(15):1137–42. PMID:16077072

222.   Carley AM, Chivukula M, Carter GJ, Karabakhtsian RG, Dabbs DJ (2008). Frequency and clinical significance of simultaneous association of lobular neoplasia and columnar cell alterations in breast tissue specimens. Am J Clin Pathol. 130(2):254–8. PMID:18628095

223.   Carlson JW, Fletcher CD (2007). Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology. 51(4):509–14. PMID:17711447

224.   Carney JA, Stratakis CA (1996). Ductal adenoma of the breast and the Carney complex. Am J Surg Pathol. 20(9):1154–5. PMID:8764753

225.   Carney JA, Toorkey BC (1991). Ductal adenoma of the breast with tubular features. A probable component of the complex of myxomas, spotty pigmentation, endocrine overactivity, and schwannomas. Am J Surg Pathol. 15(8):722–31. PMID:2069210

226.   Carney JA, Toorkey BC (1991). Myxoid fibroadenoma and allied conditions (myxomatosis) of the breast. A heritable disorder with special associations including cardiac and cutaneous myxomas. Am J Surg Pathol. 15(8):713–21. PMID:2069209

227.   Carstens PH, Greenberg RA, Francis D, Lyon H (1985). Tubular carcinoma of the breast. A long term follow-up. Histopathology. 9(3):271–80. PMID:2987100

228.   Cartagena N Jr, Cabello-Inchausti B, Willis I, Poppiti R Jr (1988). Clear cell myoepithelial neoplasm of the breast. Hum Pathol. 19(10):1239–43. PMID:2844648

228A.   Carter BA, Jensen RA, Simpson JF, Page DL (2000). Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol. 113(2):259–65. PMID:10664628

229.   Carter BA, Page DL, Schuyler P, Parl FF, Simpson JF, Jensen RA, et al. (2001). No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia. Cancer. 92(1):30–6. PMID:11443606

230.   Carter CL, Allen C, Henson DE (1989). Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 63(1):181–7. PMID:2910416

231.   Carter D (1977). Intraductal papillary tumors of the breast: a study of 78 cases. Cancer. 39(4):1689–92. PMID:851947

232.   Carter D, Orr SL, Merino MJ (1983). Intracystic papillary carcinoma of the breast. After mastectomy, radiotherapy or excisional biopsy alone. Cancer. 52(1):14–9. PMID:6850536

233.   Carter MR, Hornick JL, Lester S, Fletcher CD (2006). Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol. 30(3):300–9. PMID:16538049

233A.   Caruso G, Ienzi R, Piovana G, Ricotta V, Cirino A, Salvaggio G, et al. (2004). High-frequency ultrasound in the study of male breast palpable masses. Radiol Med. 108(3):185–93. PMID:15343133

234.   Catalina-Fernández I, Sáenz-Santamaria J (2009). Lipid-rich carcinoma of breast: a case report with fine needle aspiration cytology. Diagn Cytopathol. 37(12):935–6. PMID:19795489

235.   Cavaciuti E, Laugé A, Janin N, Ossian K, Hall J, Stoppa-Lyonnet D, et al. (2005). Cancer risk according to type and location of ATM mutation in ataxia-telangiectasia families. Genes Chromosomes Cancer. 42(1):1–9. PMID:15390180

236.   Cavalli LR, Cornelio DA, Lima RS, Urban CA, Rone JD, Cavalli IJ, et al. (2004). Lack of DNA copy number alterations revealed with comparative genomic hybridization in fibroadenomas of the breast. Cancer Genet Cytogenet. 153(2):173–6. PMID:15350309

237.   Cawson JN, Law EM, Kavanagh AM (2001). Invasive lobular carcinoma: sonographic features of cancers detected in a BreastScreen Program. Australas Radiol. 45(1):25–30. PMID:11259968

238.   Chaignaud B, Hall TJ, Powers C, Subramony C, Scott-Conner CE (1994). Diagnosis and natural history of extramammary tumors metastatic to the breast. J Am Coll Surg. 179(1):49–53. PMID:8019724

239.   Chaiwun B, Nakrungsee S, Sukhamwang N, Srisukho S (2010). A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study. Breast Cancer. 17(1):35–41. PMID:19789946

240.   Chan KW, Ghadially FN, Alagaratnam TT (1984). Benign spindle cell tumour of breast–a variant of spindled cell lipoma or fibroma of breast? Pathology. 16(3):331–6. PMID:6514401

241.   Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, et al. (2005). Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 102(10):3738–43. PMID:15701700

242.   Chang JC, Hilsenbeck SG (2010). Prognostic and predictive markers. In: Harris JR, Lippman ME, Morrow M, Osbourne CK, editors. Diseases of the breast. 4th ed. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins; pp. 443–57.

243.   Chapellier C, Balu-Maestro C, Bleuse A, Ettore F, Bruneton JN (2000). Ultrasonography of invasive lobular carcinoma of the breast: sonographic patterns and diagnostic value: report of 102 cases. Clin Imaging. 24(6):333–6. PMID:11368932

244.   Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, et al. (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 16(1):45–55. PMID:20028757

245.   Charafe-Jauffret E, Mrad K, Intidhar Labidi S, Ben Hamida A, Ben Romdhane K, Ben Abdallah M, et al. (2007). Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast. 16(4):352–8. PMID:17360185

246.   Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, et al. (2004). Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’. J Pathol. 202(3):265–73. PMID:14991891

247.   Charpin C, Mathoulin MP, Andrac L, Barberis J, Boulat J, Sarradour B, et al. (1994). Reappraisal of breast hamartomas. A morphological study of 41 cases. Pathol Res Pract. 190(4):362–71. PMID:8078805

248.   Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J, et al. (1984). Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg. 71(9):711–4. PMID:6478165

249.   Chaudary MA, Millis RR, Lane EB, Miller NA (1986). Paget’s disease of the nipple: a ten year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat. 8(2):139–46. PMID:2434164

250.   CHEK2 Breast Cancer Case-Control Consortium (2004). CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 74(6):1175–82. PMID:15122511

250A.   Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, et al. (2004). Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 22(12):2303–12. PMID:15197191

251.   Chen CY, Sun LM, Anderson BO (2006). Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer. 107(7):1448–58. PMID:16933329

252.   Chen KT (1990). Pleomorphic adenoma of the breast. Am J Clin Pathol. 93(6):792–4. PMID:2161179

253.   Chen PC, Chen CK, Nicastri AD, Wait RB (1994). Myoepithelial carcinoma of the breast with distant metastasis and accompanied by adenomyoepitheliomas. Histopathology. 24(6):543–8. PMID:7520413

254.   Chen S, Parmigiani G (2007). Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 25(11):1329–33. PMID:17416853

255.   Chen S, Wang W, Lee S, Nafa K, Lee J, Romans K, et al.; Colon Cancer Family Registry (2006). Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA. 296(12):1479–87. PMID:17003396

256.   Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, et al. (2006). Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 166(9):1027–32. PMID:16682578

257.   Chen Y, Thompson W, Semenciw R, Mao Y (1999). Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 8(10):855–61. PMID:10548312

258.   Chen YY, Hwang ES, Roy R, DeVries S, Anderson J, Wa C, et al. (2009). Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 33(11):1683–94. PMID:19701073

259.   Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, et al.; kConFab Investigators (2006). Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res. 66(4):2019–27. PMID:16489001

260.   Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE; CIMBA (2007). An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 9(2):104. PMID:17466083

261.   Cheng J, Saku T, Okabe H, Furthmayr H (1992). Basement membranes in adenoid cystic carcinoma. An immunohistochemical study. Cancer. 69(11):2631–40. PMID:1315206

262.   Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P (1993). Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol. 16(3):223–8. PMID:8338056

262A.   Chhieng C, Cranor M, Lesser ME, Rosen PP (1998). Metaplastic carcinoma of the breast with osteocartilaginous heterologous elements. Am J Surg Pathol. 22(2):188–94. PMID:9500219

262B.   Chia Y, Thike AA, Cheok PY, Yong-Zheng Chong L, Man-Kit Tse G, Tan PH (2012). Stromal keratin expression in phyllodes tumours of the breast: a comparison with other spindle cell breast lesions. J Clin Pathol. 65(4):339–47. PMID:22259180

262C.   Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, et al. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 10(6):529–41. PMID:17157792

262D.   Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, et al. (2007). High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 8(10):R215. PMID:17925008

263.   Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al.; WHI Investigators (2010). Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 304(15):1684–92. PMID:20959578

264.   Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al.; WHI Investigators (2003). Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA. 289(24):3243–53. PMID:12824205

265.   Chompret A, Abel A, Stoppa-Lyonnet D, Brugiéres L, Pagés S, Feunteun J, et al. (2001). Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 38(1):43–7. PMID:11332399

266.   Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, et al. (2000). P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer. 82(12):1932–7. PMID:10864200

267.   Chong LY, Cheok PY, Tan WJ, Thike AA, Allen G, Ang MK, et al. (2011). Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification. Breast Cancer Res Treat. PMID:21574054

267A.   Chua CL, Thomas A, Ng BK (1988). Cystosarcoma phyllodes–Asian variations. Aust N Z J Surg. 58(4):301–5. PMID:2855393

268.   Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, et al. (2005). Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol. 23(24):5534–41. PMID:16110014

269.   Chun HH, Gatti RA (2004). Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst). 3(8-9):1187–96. PMID:15279807

270.   Clarke C, Sandle J, Lakhani SR (2005). Myoepithelial cells: pathology, cell separation and markers of myoepithelial differentiation. J Mammary Gland Biol Neoplasia. 10(3):273–80. PMID:16807806

271.   Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, et al.; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 366(9503):2087–106. PMID:16360786

272.   Clarke RB (2003). Steroid receptors and proliferation in the human breast. Steroids. 68(10-13):789–94. PMID:14667969

272A.   Clement PB, Azzopardi JG (1983). Microglandular adenosis of the breast–a lesion simulating tubular carcinoma. Histopathology. 7(2):169–80. PMID:6852780

273.   Clement PB, Young RH, Azzopardi JG (1987). Collagenous spherulosis of the breast. Am J Surg Pathol. 11(6):411–7. PMID:3035952

273A.   Cleton-Jansen AM (2002). E-cadherin and loss of heterozygosity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res. 4(1):5–8. PMID:11879552

273B.   Cleton-Jansen AM, Buerger H, Haar Nt, Philippo K, van de Vijver MJ, Boecker W, et al. (2004). Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer. 41(2):109–16. PMID:15287023

274.   Clune JE, Kozakewich HP, VanBeek CA, Labow BI, Greene AK (2009). Nipple adenoma in infancy. J Pediatr Surg. 44(11):2219–22. PMID:19944237

275.   Coarasa-Cerdán A, Palomo-Jimenez M, Montero-Montero A, Alegre-Bernal N, Guadaño-Salvadores V (1998). Hemangiopericytoma of the breast: mammographic and sonographic findings. J Clin Ultrasound. 26(3):155–8. PMID:9580194

276.   Coffin CM, Hornick JL, Fletcher CD (2007). Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 31(4):509–20. PMID:17414097

277.   Coffin CM, Humphrey PA, Dehner LP (1998). Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Semin Diagn Pathol. 15(2):85–101. PMID:9606801

278.   Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. (1995). The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 332(24):1589–93. PMID:7753136

279.   Colditz GA, Rosner B (2000). Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses’ Health Study. Am J Epidemiol. 152(10):950–64. PMID:11092437

280.   Collaborative Group on Hormonal Factors in Breast Cancer (1996). Breast cancer and hormonal contraceptives: further results. Contraception. 54(3) Suppl:1S–106S. PMID:8899264

281.   Collaborative Group on Hormonal Factors in Breast Cancer (1997). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 350(9084):1047–59. PMID:10213546

282.   Collaborative Group on Hormonal Factors in Breast Cancer (2001). Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 358(9291):1389–99. PMID:11705483

283.   Collins LC, Baer HJ, Tamimi RM, Connolly JL, Colditz GA, Schnitt SJ (2006). The influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses’ Health Study. Cancer. 107(6):1240–7. PMID:16902983

284.   Collins LC, Carlo VP, Hwang H, Barry TS, Gown AM, Schnitt SJ (2006). Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol. 30(8):1002–7. PMID:16861972

285.   Collins LC, Connolly JL, Page DL, Goulart RA, Pisano ED, Fajardo LL, et al. (2004). Diagnostic agreement in the evaluation of image-guided breast core needle biopsies: results from a randomized clinical trial. Am J Surg Pathol. 28(1):126–31. PMID:14707874

286.   Collins LC, Schnitt SJ (2008). Papillary lesions of the breast: selected diagnostic and management issues. Histopathology. 52(1):20–9. PMID:18171414

286A.   Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ (2005). Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses’ Health Study. Cancer. 103(9):1778–84. PMID:15770688

287.   Collishaw N, Boyd NF, Hammond SK, Johnson KC, Millar J, Miller B (2009). Canadian Expert Panel on Tobacco Smoke and Breast Cancer Risk. Toronto, Canada: Ontario Tobacco Research Unit.

288.   Concannon P, Haile RW, Børresen-Dale AL, Rosenstein BS, Gatti RA, Teraoka SN, et al.; Women’s Environment, Cancer, and Radiation Epidemiology Study Collaborative Group (2008). Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res. 68(16):6486–91. PMID:18701470

289.   Corradi D, Bosio S, Maestri R, Mormandi F, Curry A, Eyden B (2008). A giant myxoid mammary myofibroblastoma: evidence for a myogenic/synthetic phenotype and an extracellular matrix rich in fibronectin. Histopathology. 52(3):396–9. PMID:18081816

290.   Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, et al.; Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer; Breast Cancer Association Consortium (2007). A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet. 39(3):352–8. PMID:17293864

291.   Cox CE, Nguyen K, Gray RJ, Salud C, Ku NN, Dupont E, et al. (2001). Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 67(6):513–9, discussion 519–21. PMID:11409797

292.   Coyne JD (2001). Apocrine ductal carcinoma in-situ with an unusual morphological presentation. Histopathology. 38(3):280. PMID:11260313

293.   Crisi GM, Marconi SA, Makari-Judson G, Goulart RA (2005). Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol. 124(5):733–9. PMID:16203286

294.   Cristofanilli M (2010). Novel targeted therapies in inflammatory breast cancer. Cancer. 116(11) Suppl:2837–9. PMID:20503416

295.   Cristofanilli M, Buchholz TA (2010). Proceedings of the First International Inflammatory Breast Cancer Conference. Cancer. 116(11) Suppl:2729. PMID:20503400

296.   Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, et al. (1998). p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene. 17(13):1681–9. PMID:9796697

297.   Cserni G (2007). Pathological evaluation of sentinel lymph nodes. Surg Oncol Clin N Am. 16(1):17–34. PMID:17336234

298.   Cserni G, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, Boecker W, et al. (2004). Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol. 57(7):695–701. PMID:15220360

299.   Cserni G, Bianchi S, Vezzosi V, Peterse H, Sapino A, Arisio R, et al. (2006). The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel lymph nodes in patients with lobular breast carcinoma. J Clin Pathol. 59(5):518–22. PMID:16497870

300.   Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, et al. (2005). Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 117(6):988–91. PMID:15986445

301.   d’Amore ES, Terrier-Lacombe MJ, Travagli JP, Friedman S, Contesso G (1988). Invasive apocrine carcinoma of the breast: a long term follow-up study of 34 cases. Breast Cancer Res Treat. 12(1):37–44. PMID:2848603

302.   D’Angelo P, Carli M, Ferrari A, Manzitti C, Mura R, Miglionico L, et al.; AIEOP Soft Tissue Sarcoma Committee (2010). Breast metastases in children and adolescents with rhabdomyosarcoma: Experience of the Italian Soft Tissue Sarcoma Committee. Pediatr Blood Cancer. 55(7):1306–9. PMID:20730885

303.   Da Silva L, Parry S, Reid L, Keith P, Waddell N, Kossai M, et al. (2008). Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol. 32(5):773–83. PMID:18379416

304.   Dabbs DJ, Bhargava R, Chivukula M (2007). Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am J Surg Pathol. 31(3):427–37. PMID:17325485

305.   Dahlén A, Debiec-Rychter M, Pedeutour F, Domanski HA, Höglund M, Bauer HC, et al. (2003). Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer. 103(5):616–23. PMID:12494468

306.   Dal Cin P, Wanschura S, Christiaens MR, Van den Berghe I, Moerman P, Polito P, et al. (1997). Hamartoma of the breast with involvement of 6p21 and rearrangement of HMGIY. Genes Chromosomes Cancer. 20(1):90–2. PMID:9290959

307.   Dalberg K, Hellborg H, Wärnberg F (2008). Paget’s disease of the nipple in a population based cohort. Breast Cancer Res Treat. 111(2):313–9. PMID:17952590

308.   Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, et al. (2002). Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer. 95(12):2455–64. PMID:12467057

309.   Damera A, Evans AJ, Cornford EJ, Wilson AR, Burrell HC, James JJ, et al. (2003). Diagnosis of axillary nodal metastases by ultrasound-guided core biopsy in primary operable breast cancer. Br J Cancer. 89(7):1310–3. PMID:14520465

310.   Damiani S, Chiodera P, Guaragni M, Eusebi V (2002). Mammary angiomyolipoma. Virchows Arch. 440(5):551–2. PMID:12021933

311.   Damiani S, Eusebi V (2001). Gynecomastia in type-1 neurofibromatosis with features of pseudoangiomatous stromal hyperplasia with giant cells. Report of two cases. Virchows Arch. 438(5):513–6. PMID:11407482

312.   Damiani S, Eusebi V, Losi L, D’Adda T, Rosai J (1998). Oncocytic carcinoma (malignant oncocytoma) of the breast. Am J Surg Pathol. 22(2):221–30. PMID:9500224

313.   Damiani S, Miettinen M, Peterse JL, Eusebi V (1994). Solitary fibrous tumour (myofibroblastoma) of the breast. Virchows Arch. 425(1):89–92. PMID:7921419

314.   Damiani S, Pasquinelli G, Lamovec J, Peterse JL, Eusebi V (2000). Acinic cell carcinoma of the breast: an immunohistochemical and ultrastructural study. Virchows Arch. 437(1):74–81. PMID:10963383

315.   Dammers JW (1991). [Carpal tunnel syndrome]. Ned Tijdschr Geneeskd. 135(5):193–4. PMID:2002875

316.   Daneshbod Y, Oryan A, Khojasteh HN, Rasekhi A, Ahmadi N, Mohammadianpanah M (2010). Primary ALK-positive anaplastic large cell lymphoma of the breast: a case report and review of the literature. J Pediatr Hematol Oncol. 32(2):e75–8. PMID:20168249

317.   Daniel BL, Gardner RW, Birdwell RL, Nowels KW, Johnson D (2003). Magnetic resonance imaging of intraductal papilloma of the breast. Magn Reson Imaging. 21(8):887–92. PMID:14599539

317A.   Davis WG, Hennessy B, Babiera G, Hunt K, Valero V, Buchholz TA, et al. (2005). Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol. 29(11):1456–63. PMID:16224212

318.   Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, et al. (2010). Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Am J Clin Pathol. 103:685–9.

319.   Daya D, Trus T, D’Souza TJ, Minuk T, Yemen B (1995). Hamartoma of the breast, an underrecognized breast lesion. A clinicopathologic and radiographic study of 25 cases. Am J Clin Pathol. 103(6):685–9. PMID:7785651

320.   De Brakeleer S, De Grève J, Loris R, Janin N, Lissens W, Sermijn E, et al. (2010). Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. Hum Mutat. 31(3):E1175–85. PMID:20077502

321.   de Jong D, Vasmel WL, de Boer JP, Verhave G, Barbé E, Casparie MK, et al. (2008). Anaplastic large-cell lymphoma in women with breast implants. JAMA. 300(17):2030–5. PMID:18984890

322.   De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, et al. (1997). Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 183(4):404–11. PMID:9496256

323.   de Leeuw WJ, van Puijenbroek M, Tollenaar RA, Cornelisse CJ, Vasen HF, Morreau H (2003). Correspondence re: A. Müller et al., Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res., 62: 1014–1019, 2002. Cancer Res. 63(5):1148–9. PMID:12615735

324.   de Mascarel I, Bonichon F, Durand M, Mauriac L, MacGrogan G, Soubeyran I, et al. (1998). Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. Eur J Cancer. 34(1):58–65. PMID:9624238

324A.   de Roos WK, Kaye P, Dent DM (1999). Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast. Br J Surg. 86(3):396–9. PMID:10201787

325.   de Winter JP, Joenje H (2009). The genetic and molecular basis of Fanconi anemia. Mutat Res. 668(1-2):11–9. PMID:19061902

326.   Dean-Colomb W, Esteva FJ (2008). Her2-positive breast cancer: herceptin and beyond. Eur J Cancer. 44(18):2806–12. PMID:19022660

327.   Decorsière JB, Thibaut I, Bouissou H (1988). [Adeno-myoepithelial proliferation in the breast]. Ann Pathol. 8(4-5):311–6. PMID:2850809

328.   delli Santi G, Bellioni M, Loreti A, Stagnitto D, La Pinta M, Dell’Osso A (2006). Giant breast lipoma: a rare cause of breast asymmetry. Plast Reconstr Surg. 117(3):1068–9. PMID:16525337

329.   Dendale R, Vincent-Salomon A, Mouret-Fourme E, Savignoni A, Medioni J, Campana F, et al. (2003). Medullary breast carcinoma: prognostic implications of p53 expression. Int J Biol Markers. 18(2):99–105. PMID:12841678

330.   Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS (1996). Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science. 274(5295):2057–9. PMID:8953032

331.   Denley H, Pinder SE, Tan PH, Sim CS, Brown R, Barker T, et al. (2000). Metaplastic carcinoma of the breast arising within complex sclerosing lesion: a report of five cases. Histopathology. 36(3):203–9. PMID:10692021

331A.   Desmedt C, Giobbie-Hurder A, Neven P, Paridaens R, Christiaens MR, Smeets A, et al. (2009). The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1–98 trial. BMC Med Genomics. 2:40. PMID:19573224

331B.   Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, et al. (2006). Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell. 10(5):437–49. PMID:17097565

332.   Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. (2008). Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 14(16):5158–65. PMID:18698033

333.   Devouassoux-Shisheboran M, Schammel MD, Man YG, Tavassoli FA (2000). Fibromatosis of the breast: age-correlated morphofunctional features of 33 cases. Arch Pathol Lab Med. 124(2):276–80. PMID:10656738

334.   Dewar R, Fadare O, Gilmore H, Gown AM (2011). Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med. 135(4):422–9. PMID:21466356

335.   Dhingra KK, Mandal S, Roy S, Khurana N (2007). Malignant peripheral nerve sheath tumor of the breast: case report. World J Surg Oncol. 5:142. PMID:18154670

336.   Di Cristofano C, Mrad K, Zavaglia K, Bertacca G, Aretini P, Cipollini G, et al. (2005). Papillary lesions of the breast: a molecular progression? Breast Cancer Res Treat. 90(1):71–6. PMID:15770529

337.   Di Saverio S, Gutierrez J, Avisar E (2008). A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat. 111(3):541–7. PMID:18026874

338.   Di Tommaso L, Foschini MP, Ragazzini T, Magrini E, Fornelli A, Ellis IO, et al. (2004). Mucoepidermoid carcinoma of the breast. Virchows Arch. 444(1):13–9. PMID:14634807

339.   Di Tommaso L, Franchi G, Destro A, Broglia F, Minuti F, Rahal D, et al. (2008). Toker cells of the breast. Morphological and immunohistochemical characterization of 40 cases. Hum Pathol. 39(9):1295–300. PMID:18614197

340.   Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM (1999). Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 17(5):1442–8. PMID:10334529

341.   DiCostanzo D, Rosen PP, Gareen I, Franklin S, Lesser M (1990). Prognosis in infiltrating lobular carcinoma. An analysis of “classical” and variant tumors. Am J Surg Pathol. 14(1):12–23. PMID:2153007

342.   Dietzel M, Baltzer PA, Vag T, Gröschel T, Gajda M, Camara O, et al. (2010). Magnetic resonance mammography of invasive lobular versus ductal carcinoma: systematic comparison of 811 patients reveals high diagnostic accuracy irrespective of typing. J Comput Assist Tomogr. 34(4):587–95. PMID:20657229

343.   Dina R, Eusebi V (1997). Clear cell tumors of the breast. Semin Diagn Pathol. 14(3):175–82. PMID:9279974

343A.   Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. (2010). Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 464(7291):999–1005. PMID:20393555

344.   Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL (2010). Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat. PMID:20927582

345.   Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW (1982). Infiltrating lobular carcinoma of the breast. Histopathology. 6(2):149–61. PMID:7076138

346.   Dixon JM, Sainsbury JRC (1998). Handbook of diseases of the breast. 2nd ed. London: Churchill Livingstone.

346A.   Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, et al. (2006). An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 25(28):3994–4008. PMID:16491124

347.   Doctor VM, Sirsat MV (1971). Florid papillomatosis (adenoma) and other benign tumours of the nipple and areola. Br J Cancer. 25(1):1–9. PMID:5581295

348.   Domagala W, Harezga B, Szadowska A, Markiewski M, Weber K, Osborn M (1993). Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol. 142(3):669–74. PMID:8384406

349.   Domfeh AB, Carley AL, Striebel JM, Karabakhtsian RG, Florea AV, McManus K, et al. (2008). WT1 immunoreactivity in breast carcinoma: selective expression in pure and mixed mucinous subtypes. Mod Pathol. 21(10):1217–23. PMID:18469795

350.   Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, et al. (2010). Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 116(12):2884–9. PMID:20564395

351.   Domoto H, Terahata S, Sato K, Tamai S (1998). Nodular hidradenoma of the breast: report of two cases with literature review. Pathol Int. 48(11):907–11. PMID:9832062

352.   Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356(6366):215–21. PMID:1552940

353.   Douglas-Jones AG, Pace DP (1997). Pathology of R4 spiculated lesions in the breast screening programme. Histopathology. 30(3):214–20. PMID:9088949

353A.   Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. (2010). Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 28(11):1829–34. PMID:20212256

353B.   Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ (2009). Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol. 33(4):534–41. PMID:19047898

354.   Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR (2001). Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer. 92(3):404–8. PMID:11291078

354A.   Drudis T, Arroyo C, Van Hoeven K, Cordon-Cardo C, Rosen PP (1994). The pathology of low-grade adenosquamous carcinoma of the breast. An immunohistochemical study. Pathol Annu. 29(Pt 2):181–97. PMID:7936747

355.   du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Blamey RW (1989). Invasive lobular carcinomas of the breast–the prognosis of histopathological subtypes. Br J Cancer. 60(4):605–9. PMID:2803932

356.   Dunne B, Lee AH, Pinder SE, Bell JA, Ellis IO (2003). An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol. 34(10):1009–15. PMID:14608534

356A.   Dunning MJ, Curtis C, Barbosa-Morais NL, Caldas C, Tavaré S, Lynch AG (2010). The importance of platform annotation in interpreting microarray data. Lancet Oncol. 11(8):717. PMID:20688273

357.   Dupont WD, Page DL (1985). Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 312(3):146–51. PMID:3965932

358.   Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr, Rados MS, et al. (1994). Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 331(1):10–5. PMID:8202095

359.   Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, et al. (1993). Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 71(4):1258–65. PMID:8435803

359A.   Duprez R, Wilkerson PM, Lacroix-Triki M, Lambros MB, Mackay A, Hern RA, et al. (2012). Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol. 226(3):427–41. PMID:22025283

360.   Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365(9472):1687–717. PMID:15894097

361.   Easton DF (1999). How many more breast cancer predisposition genes are there? Breast Cancer Res. 1(1):14–7. PMID:11250676

362.   Easton DF, Bishop DT, Ford D, Crockford GP; The Breast Cancer Linkage Consortium (1993). Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet. 52(4):678–701. PMID:8460634

363.   Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, et al. (2007). A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 81(5):873–83. PMID:17924331

364.   Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al.; SEARCH collaborators; kConFab; AOCS Management Group (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 447(7148):1087–93. PMID:17529967

365.   Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, et al. (1997). Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12–13. Am J Hum Genet. 61(1):120–8. PMID:9245992

366.   Edge SB, Byrd DR, editors. (2010). AJCC cancer staging manual. 7th ed. New York: Springer.

367.   Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al.; Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators; British Association of Urological Surgeons Section of Oncology (2003). Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 72(1):1–12. PMID:12474142

368.   Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, et al. (1998). Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res. 58(8):1588–92. PMID:9563465

369.   Eisinger F, Noguès C, Birnbaum D, Jacquemier J, Sobol H (1998). BRCA1 and medullary breast cancer. JAMA. 280(14):1227–8. PMID:9786365

370.   El Aouni N, Laurent I, Terrier P, Mansouri D, Suciu V, Delaloge S, et al. (2007). Granular cell tumor of the breast. Diagn Cytopathol. 35(11):725–7. PMID:17924412

371.   El Wakil A, Doghman M, Latre De Late P, Zambetti GP, Figueiredo BC, Lalli E (2011). Genetics and genomics of childhood adrenocortical tumors. Mol Cell Endocrinol. 336(1-2):169–73. PMID:21094206

372.   El-Sayed ME, Rakha EA, Reed J, Lee AH, Evans AJ, Ellis IO (2008). Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Histopathology. 53(6):650–7. PMID:19076681

373.   Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2006). Adult weight change and risk of postmenopausal breast cancer. JAMA. 296(2):193–201. PMID:16835425

374.   Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, et al. (2006). Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst. 98(19):1406–15. PMID:17018787

375.   Ellis DL, Teitelbaum SL (1974). Inflammatory carcinoma of the breast. A pathologic definition. Cancer. 33(4):1045–7. PMID:4819210

376.   Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW (1992). Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. Histopathology. 20(6):479–89. PMID:1607149

376A.   Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. (2011). Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 29(17):2342–9. PMID:21555689

377.   Elston CW, Ellis IO (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19(5):403–10. PMID:1757079

378.   Elston CW, Ellis IO, editors. (1998). Systemic pathology. The breast. Volume 13. 3rd ed. Edinburgh, New York: Churchill Livingstone.

379.   Elston CW, Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, et al.; European Commission Working Group on Breast Screening Pathology (2000). Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. Eur J Cancer. 36(14):1769–72. PMID:10974624

380.   Ende L, Mercado C, Axelrod D, Darvishian F, Levine P, Cangiarella J (2007). Intraparenchymal leiomyoma of the breast: a case report and review of the literature. Ann Clin Lab Sci. 37(3):268–73. PMID:17709693

381.   Eng C (2000). Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet. 37(11):828–30. PMID:11073535

382.   Eng C (2003). PTEN: one gene, many syndromes. Hum Mutat. 22(3):183–98. PMID:12938083

383.   Epstein M, Ma Y, Press MF (2010). ERBB2 testing: assessment of status for targeted therapies. In: Harris JR, Lippman ME, Morrow M, Osbourne CK, editors. Diseases of the breast. 4th ed. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins; pp. 431–42.

384.   Erhan Y, Erhan Y, Zekioğlu O (2005). Pure invasive micropapillary carcinoma of the male breast: report of a rare case. Can J Surg. 48(2):156–7. PMID:15887800

384A.   Erickson-Johnson MR, Chou MM, Evers BR, Roth CW, Seys AR, Jin L, et al. (2011). Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab Invest. 91(10):1427–33. PMID:21826056

385.   Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, et al. (2007). A recurrent mutation in PALB2 in Finnish cancer families. Nature. 446(7133):316–9. PMID:17287723

386.   Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, et al. (2002). Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 94(20):1546–54. PMID:12381707

387.   Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R (2000). Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med. 160(7):953–8. PMID:10761960

388.   Esposito NN, Dabbs DJ, Bhargava R (2009). Are encapsulated papillary carcinomas of the breast in situ or invasive? A basement membrane study of 27 cases. Am J Clin Pathol. 131(2):228–42. PMID:19141383

389.   Etzell JE, Devries S, Chew K, Florendo C, Molinaro A, Ljung BM, et al. (2001). Loss of chromosome 16q in lobular carcinoma in situ. Hum Pathol. 32(3):292–6. PMID:11274638

390.   Eusebi V, Betts C, Haagensen DE Jr, Gugliotta P, Bussolati G, Azzopardi JG (1984). Apocrine differentiation in lobular carcinoma of the breast: a morphologic, immunologic, and ultrastructural study. Hum Pathol. 15(2):134–40. PMID:6365733

391.   Eusebi V, Casadei GP, Bussolati G, Azzopardi JG (1987). Adenomyoepithelioma of the breast with a distinctive type of apocrine adenosis. Histopathology. 11(3):305–15. PMID:2828217

392.   Eusebi V, Cattani MG, Ceccarelli C, Lamovec J (1989). Sarcomatoid carcinomas of the breast: an immunocytochemical study of 14 cases. Recent Progr Surg Pathol. 9:83–99.

393.   Eusebi V, Cunsolo A, Fedeli F, Severi B, Scarani P (1980). Benign smooth muscle cell metaplasia in breast. Tumori. 66(5):643–53. PMID:7466927

394.   Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, et al. (1994). Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol. 11(3):223–35. PMID:7831534

395.   Eusebi V, Foschini MP, Bussolati G, Rosen PP (1995). Myoblastomatoid (histiocytoid) carcinoma of the breast. A type of apocrine carcinoma. Am J Surg Pathol. 19(5):553–62. PMID:7726365

396.   Eusebi V, Magalhaes F, Azzopardi JG (1992). Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol. 23(6):655–62. PMID:1592388

397.   Eusebi V, Millis RR (2010). Epitheliosis, infiltrating epitheliosis, and radial scar. Semin Diagn Pathol. 27(1):5–12. PMID:20306826

398.   Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG (1986). Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am J Pathol. 123(3):532–41. PMID:3717305

398A.   Eusebi V, Lamovec J, Cattani MG, Fedeli F, Millis RR (1986). Acantholytic variant of squamous-cell carcinoma of the breast. Am J Surg Pathol. 10(12):855–61. PMID:2431630

399.   Evans DG, Birch JM, Narod SA (2008). Is CHEK2 a cause of the Li-Fraumeni syndrome? J Med Genet. 45(1):63–4. PMID:18178638

400.   Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, et al. (2004). A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 41(6):474–80. PMID:15173236

401.   Evans DG, Lalloo F, Cramer A, Jones EA, Knox F, Amir E, et al. (2009). Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet. 46(12):811–7. PMID:19542080

402.   Evans DG, Lalloo F, Wallace A, Rahman N (2005). Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet. 42(7):e39. PMID:15994864

403.   Evans DG, Lunt P, Clancy T, Eeles R (2010). Childhood predictive genetic testing for Li-Fraumeni syndrome. Fam Cancer. 9(1):65–9. PMID:19404774

404.   Evans DG, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F (2010). Risk of breast cancer in male BRCA2 carriers. J Med Genet. 47(10):710–1. PMID:20587410

405.   Evans DG, Wu CL, Birch JM (2008). BRCA2: a cause of Li-Fraumeni-like syndrome. J Med Genet. 45(1):62–3. PMID:18178637

406.   Evans H, Bridge J (2002). Nodular fasciitis. In: Pathology and genetics of tumours of soft tissue and bone.Fletcher CDM, Unni KK, Mertens F, eds. WHO Classification of Tumours, 3rd edition. IARCPress: Lyon: pp 48–49.

407.   Evans HL, Batsakis JG (1984). Polymorphous low-grade adenocarcinoma of minor salivary glands. A study of 14 cases of a distinctive neoplasm. Cancer. 53(4):935–42. PMID:6692293

408.   Evans HL, Luna MA (2000). Polymorphous low-grade adenocarcinoma: a study of 40 cases with long-term follow up and an evaluation of the importance of papillary areas. Am J Surg Pathol. 24(10):1319–28. PMID:11023093

409.   Evans N, Lyons K (2000). The use of ultrasound in the diagnosis of invasive lobular carcinoma of the breast less than 10 mm in size. Clin Radiol. 55(4):261–3. PMID:10767184

410.   Ewald IP, Ribeiro PLI, Palmero EI, Cossio SL, Giugliani R, Ashton-Prolla P (2009). Genomic rearrangements in BRCA1 and BRCA2: A literature review. Mol Biol. 32:437–46. PMID:21637503

411.   Fackenthal JD, Marsh DJ, Richardson AL, Cummings SA, Eng C, Robinson BG, et al. (2001). Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 38(3):159–64. PMID:11238682

412.   Fadare O (2006). Pleomorphic lobular carcinoma in situ of the breast composed almost entirely of signet ring cells. Pathol Int. 56(11):683–7. PMID:17040292

413.   Fadare O, Wang SA, Hileeto D (2008). The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset? Hum Pathol. 39(3):331–6. PMID:18261623

414.   Faille A, De Cremoux P, Extra JM, Linares G, Espie M, Bourstyn E, et al. (1994). p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer. 69(6):1145–50. PMID:8198984

415.   Falconieri G, Della Libera D, Zanconati F, Bittesini L (1997). Leiomyosarcoma of the female breast: report of two new cases and a review of the literature. Am J Clin Pathol. 108(1):19–25. PMID:9208974

416.   Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. (2006). Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 355(6):560–9. PMID:16899776

417.   Fan F, Smith W, Wang X, Jewell W, Thomas PA, Tawfik O (2007). Myoepithelial carcinoma of the breast arising in an adenomyoepithelioma: mammographic, ultrasound and histologic features. Breast J. 13(2):203–4. PMID:17319866

418.   Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, et al. (2010). Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PLoS One. 5(5):e10813. PMID:20520810

419.   Fang ZM, Tse RV, Marjoniemi VM, Kozlov S, Lavin MF, Chen H, et al. (2009). Radioresistant malignant myoepithelioma of the breast with high level of ataxia telangiectasia mutated protein. J Med Imaging Radiat Oncol. 53(2):234–9. PMID:19527373

420.   Fangfang L, Danhua S, Songlin L, Yanfeng Z (2010). An unusual breast malignant peripheral nerve sheath tumour and review of the literature. J Clin Pathol. 63(7):663–4. PMID:20591921

421.   Farinha P, André S, Cabeçadas J, Soares J (2002). High frequency of MALT lymphoma in a series of 14 cases of primary breast lymphoma. Appl Immunohistochem Mol Morphol. 10(2):115–20. PMID:12051628

422.   Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. (2005). Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 24(29):4660–71. PMID:15897907

423.   Farshid G, Balleine RL, Cummings M, Waring P; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab) (2006). Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol. 30(11):1357–66. PMID:17063074

424.   Farshid G, Moinfar F, Meredith DJ, Peiterse S, Tavassoli FA (2001). Spindle cell ductal carcinoma in situ. An unusual variant of ductal intra-epithelial neoplasia that simulates ductal hyperplasia or a myoepithelial proliferation. Virchows Arch. 439(1):70–7. PMID:11499843

425.   Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S, et al. (2007). Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 18(12):2030–6. PMID:17974557

426.   Fechner RE (1972). Infiltrating lobular carcinoma without lobular carcinoma in situ. Cancer. 29(6):1539–45. PMID:4337952

427.   Fechner RE (1975). Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol. 6(3):373–8. PMID:166034

428.   Fedko MG, Scow JS, Shah SS, Reynolds C, Degnim AC, Jakub JW, et al. (2010). Pure tubular carcinoma and axillary nodal metastases. Ann Surg Oncol. 17 Suppl 3:338–42. PMID:20853056

429.   Fehr A, Kovács A, Löning T, Frierson H Jr, van den Oord J, Stenman G (2011). The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma. J Pathol. 224(3):322–7. PMID:21618541

430.   Fentiman IS, Fourquet A, Hortobagyi GN (2006). Male breast cancer. Lancet. 367(9510):595–604. PMID:16488803

431.   Fentiman IS, Millis RR, Smith P, Ellul JP, Lampejo O (1997). Mucoid breast carcinomas: histology and prognosis. Br J Cancer. 75(7):1061–5. PMID:9083343

432.   Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, editors GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer (http://globocan.iarc.fr)

433.   Ferlicot S, Vincent-Salomon A, Médioni J, Genin P, Rosty C, Sigal-Zafrani B, et al. (2004). Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer. 40(3):336–41. PMID:14746850

434.   Fernandez BB, Hernanzez FJ, Spindler W (1976). Metastatic cystosarcoma phyllodes: a light and electron microscopic study. Cancer. 37(4):1737–46. PMID:177175

435.   Fernández-Aguilar S, Simon P, Buxant F, Simonart T, Noël JC (2005). Tubular carcinoma of the breast and associated intra-epithelial lesions: a comparative study with invasive low-grade ductal carcinomas. Virchows Arch. 447(4):683–7. PMID:16091953

436.   Fernández-Ramires R, Gómez G, Muñoz-Repeto I, de Cecco L, Llort G, Cazorla A, et al. (2011). Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumors. Int J Cancer. 128(11):2635–44. PMID:20715112

437.   Ferreira M, Albarracin CT, Resetkova E (2008). Pseudoangiomatous stromal hyperplasia tumor: a clinical, radiologic and pathologic study of 26 cases. Mod Pathol. 21(2):201–7. PMID:18084246

438.   Finck FM, Schwinn CP, Keasbey LE (1968). Clear cell hidradenoma of the breast. Cancer. 22(1):125–35. PMID:4298177

439.   Fineberg S, Rosen PP (1994). Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol. 102(6):757–63. PMID:7801888

440.   Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. (1993). The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 75(5):1027–38. PMID:8252616

441.   Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. (1998). Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 16(8):2672–85. PMID:9704717

442.   Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, et al. (1999). Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 353(9169):1993–2000. PMID:10376613

443.   Fisher CJ, Hanby AM, Robinson L, Millis RR (1992). Mammary hamartoma–a review of 35 cases. Histopathology. 20(2):99–106. PMID:1559675

444.   Fisher ER, Gregorio R, Kim WS, Redmond C (1977). Lipid in invasive cancer of the breast. Am J Clin Pathol. 68(5):558–61. PMID:920651

445.   Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC (1975). The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 36(1):1–85. PMID:173455

446.   Fisher ER, Gregorio RM, Redmond C, Fisher B (1977). Tubulolobular invasive breast cancer: a variant of lobular invasive cancer. Hum Pathol. 8(6):679–83. PMID:924431

447.   Fisher ER, Land SR, Fisher B, Mamounas E, Gilarski L, Wolmark N (2004). Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 100(2):238–44. PMID:14716756

448.   Fisher ER, Palekar AS, Gregorio RM, Paulson JD (1983). Mucoepidermoid and squamous cell carcinomas of breast with reference to squamous metaplasia and giant cell tumors. Am J Surg Pathol. 7(1):15–27. PMID:6829846

449.   Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N (2002). Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 95(4):681–95. PMID:12209710

450.   Fitzgibbons PL, Henson DE, Hutter RV; Cancer Committee of the College of American Pathologists (1998). Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Arch Pathol Lab Med. 122(12):1053–5. PMID:9870852

451.   Flagiello D, Gerbault-Seureau M, Sastre-Garau X, Padoy E, Vielh P, Dutrillaux B (1998). Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer. 23(4):300–6. PMID:9824202

452.   Fletcher CDM (2007). Soft tissue tumors. In: Fletcher CDM, editor. Diagnostic histopathology of tumors. 3rd ed. Edinburgh: Churchill- Livingstone Elsevier; pp. 1527–92.

453.   Fletcher O, Johnson N, dos Santos Silva I, Orr N, Ashworth A, Nevanlinna H, et al.; kConFab Investigators; AOCS Group; GENICA Consortium; Breast Cancer Association Consortium (2010). Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomarkers Prev. 19(9):2143–51. PMID:20826828

453A.   Fletcher O, Johnson N, Orr N, Hosking FJ, Gibson LJ, Walker K, et al. (2011). Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst. 103(5):425–35. PMID:21263130

454.   Flint A, Oberman HA (1984). Infarction and squamous metaplasia of intraductal papilloma: a benign breast lesion that may simulate carcinoma. Hum Pathol. 15(8):764–7. PMID:6745916

455.   Foote FW Jr, Stewart FW (1946). A histologic classification of carcinoma of the breast. Surgery. 19:74–99. PMID:21022022

456.   Ford D, Easton DF, Peto J (1995). Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 57(6):1457–62. PMID:8533776

457.   Foschini MP, Dina RE, Eusebi V (1993). Sarcomatoid neoplasms of the breast: proposed definitions for biphasic and monophasic sarcomatoid mammary carcinomas. Semin Diagn Pathol. 10(2):128–36. PMID:8367622

458.   Foschini MP, Eusebi V (1998). Carcinomas of the breast showing myoepithelial cell differentiation. A review of the literature. Virchows Arch. 432(4):303–10. PMID:9565338

459.   Foschini MP, Krausz T (2010). Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including “triple negative carcinomas” of low malignant potential. Semin Diagn Pathol. 27(1):77–90. PMID:20306833

459A.   Foschini MP, Pizzicannella G, Peterse JL, Eusebi V (1995). Adenomyoepithelioma of the breast associated with low-grade adenosquamous and sarcomatoid carcinomas. Virchows Arch. 427(3):243–50. PMID:7496592

460.   Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 95(19):1482–5. PMID:14519755

461.   Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, et al. (2002). Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 20(6):1480–90. PMID:11896095

462.   Friberg F, Andersson EP, Bengtsson J (2007). Pedagogical encounters between nurses and patients in a medical ward–a field study. Int J Nurs Stud. 44(4):534–44. PMID:16488418

463.   Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, et al. (2006). Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer. 6:96. PMID:16620391

463A.   Friedrich RE, Hagel C (2010). Appendices of the nipple and areola of the breast in Neurofibromatosis type 1 patients are neurofibromas. Anticancer Res. 30(5):1815–7. PMID:20592384

463B.   Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. (2000). International Classification of Diseases for Oncology. 3rd ed. Geneva: World Health Organization.

464.   Frykberg ER (1999). Lobular carcinoma in situ of the breast. Breast J. 5(5):296–303. PMID:11348305

465.   Fukunaga M, Ushigome S (1997). Myofibroblastoma of the breast with diverse differentiations. Arch Pathol Lab Med. 121(6):599–603. PMID:9199625

466.   Fukuoka K, Hirokawa M, Shimizu M, Sadahira Y, Manabe T, Kurebayashi J, et al. (1999). Basaloid type adenoid cystic carcinoma of the breast. APMIS. 107(8):762–6. PMID:10515126

467.   Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, et al. (2006). Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology. 49(1):22–34. PMID:16842243

468.   Gallego Melcón S, Sánchez de Toledo Codina J (2007). Molecular biology of rhabdomyosarcoma. Clin Transl Oncol. 9(7):415–9. PMID:17652054

469.   Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, et al. (1993). Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol. 142(4):987–93. PMID:7682767

469A.   Gallager HS (1984). Pathologic types of breast cancer: their prognoses. Cancer. 53(3) Suppl:623–9. PMID:6318954

470.   Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S (2007). Non-Hodgkin lymphoma of the breast. Cancer. 110(1):25–30. PMID:17541937

471.   Gao X, Fisher SG, Emami B (2003). Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 56(4):1038–45. PMID:12829139

472.   Gapstur SM, Morrow M, Sellers TA (1999). Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA. 281(22):2091–7. PMID:10367819

473.   Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, et al.; Australian Ovarian Cancer Management Group; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (2008). Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 4(4):e1000054. PMID:18437204

474.   Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F, et al. (2010). Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat. 31(2):143–50. PMID:19877175

475.   Gatalica Z, Norris BA, Kovatich AJ (2000). Immunohistochemical localization of prostate-specific antigen in ductal epithelium of male breast. Potential diagnostic pitfall in patients with gynecomastia. Appl Immunohistochem Mol Morphol. 8(2):158–61. PMID:10937064

476.   Gatalica Z, Velagaleti G, Kuivaniemi H, Tromp G, Palazzo J, Graves KM, et al. (2005). Gene expression profile of an adenomyoepithelioma of the breast with a reciprocal translocation involving chromosomes 8 and 16. Cancer Genet Cytogenet. 156(1):14–22. PMID:15588851

477.   Gatti R, editor. (1993). Ataxia-telangiectasia. Gene reviews [Internet]. Seattle: University of Washington.

478.   Gatti RA, Tward A, Concannon P (1999). Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab. 68(4):419–23. PMID:10607471

479.   Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, et al.; GEMO Study Collaborators; HEBON Study Collaborators; OCGN; kConFab; EMBRACE (2010). Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet. 6(10):e1001183. PMID:21060860

480.   Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, et al. (1998). Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 58(18):4086–9. PMID:9751616

481.   Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, et al. (1997). Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 15(1):103–5. PMID:8988179

482.   Geary J, Sasieni P, Houlston R, Izatt L, Eeles R, Payne SJ, et al. (2008). Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer. 7(2):163–72. PMID:17939062

483.   Geddes DT (2009). Ultrasound imaging of the lactating breast: methodology and application. Int Breastfeed J. 4:4. [Abstract] PMID:19402903

484.   Gengler C, Guillou L (2006). Solitary fibrous tumour and haemangiopericytoma: evolution of a concept. Histopathology. 48(1):63–74. PMID:16359538

485.   Georgiannos SN, Chin J, Goode AW, Sheaff M (2001). Secondary neoplasms of the breast: a survey of the 20th Century. Cancer. 92(9):2259–66. PMID:11745279

485A.   Gersell DJ, Katzenstein AL (1981). Spindle cell carcinoma of the breast. A clinocopathologic and ultrastructural study. Hum Pathol. 12(6):550–61. PMID:7275095

485B.   Geyer FC, Lambros MB, Natrajan R, Mehta R, Mackay A, Savage K, et al. (2010). Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. Mod Pathol. 23(7):951–60. PMID:20453835

485C.   Geyer FC, Weigelt B, Natrajan R, Lambros MB, de Biase D, Vatcheva R, et al. (2010). Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol. 220(5):562–73. PMID:20099298

486.   Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores GM (2010). Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study. Breast Cancer Res. 12(4):R54. PMID:20653964

487.   Giannotti Filho O, Miiji LN, Vainchenker M, Gordan AN (2001). Breast cancer with choriocarcinomatous and neuroendocrine features. Sao Paulo Med J. 119(4):154–5. PMID:11500791

488.   Giardini R, Piccolo C, Rilke F (1992). Primary non-Hodgkin’s lymphomas of the female breast. Cancer. 69(3):725–35. PMID:1730123

489.   Gibbons D, Leitch M, Coscia J, Lindberg G, Molberg K, Ashfaq R, et al. (2000). Fine needle aspiration cytology and histologic findings of granular cell tumor of the breast: review of 19 cases with clinical/radiologic correlation. Breast J. 6(1):27–30. PMID:11348331

489A.   Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, et al. (2008). Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 7(4):944–51. PMID:18413808

489B.   Gillett CE, Bobrow LG, Millis RR (1990). S100 protein in human mammary tissue–immunoreactivity in breast carcinoma, including Paget’s disease of the nipple, and value as a marker of myoepithelial cells. J Pathol. 160(1):19–24. PMID:2156036

490.   Gimm O, Attié-Bitach T, Lees JA, Vekemans M, Eng C (2000). Expression of the PTEN tumour suppressor protein during human development. Hum Mol Genet. 9(11):1633–9. PMID:10861290

491.   Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, et al. (2009). The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Fam Cancer. 8(4):563–7. PMID:19714488

492.   Giordano SH, Buzdar AU, Hortobagyi GN (2002). Breast cancer in men. Ann Intern Med. 137(8):678–87. PMID:12379069

493.   Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004). Breast carcinoma in men: a population-based study. Cancer. 101(1):51–7. PMID:15221988

494.   Giri DD, Dundas SA, Nottingham JF, Underwood JC (1989). Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology. 15(6):575–84. PMID:2606454

495.   Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. (2011). Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 305(6):569–75. PMID:21304082

496.   Glazebrook KN, Reynolds C, Smith RL, Gimenez EI, Boughey JC (2010). Adenoid cystic carcinoma of the breast. AJR Am J Roentgenol. 194(5):1391–6. PMID:20410430

497.   Gleason BC, Hornick JL (2008). Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol. 61(4):428–37. PMID:17938159

498.   Gobbi H, Jensen RA, Simpson JF, Olson SJ, Page DL (2001). Atypical ductal hyperplasia and ductal carcinoma in situ of the breast associated with perineural invasion. Hum Pathol. 32(8):785–90. PMID:11521220

499.   Gobbi H, Simpson JF, Borowsky A, Jensen RA, Page DL (1999). Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. Cancer. 85(10):2170–82. PMID:10326695

499A.   Gobbi H, Simpson JF, Jensen RA, Olson SJ, Page DL (2003). Metaplastic spindle cell breast tumors arising within papillomas, complex sclerosing lesions, and nipple adenomas. Mod Pathol. 16(9):893–901. PMID:13679453

500.   Gobbi H, Tse G, Page DL, Olson SJ, Jensen RA, Simpson JF (2000). Reactive spindle cell nodules of the breast after core biopsy or fine-needle aspiration. Am J Clin Pathol. 113(2):288–94. PMID:10664632

501.   Gocht A, Bösmüller HC, Bässler R, Tavassoli FA, Moinfar F, Katenkamp D, et al. (1999). Breast tumors with myofibroblastic differentiation: clinico-pathological observations in myofibroblastoma and myofibrosarcoma. Pathol Res Pract. 195(1):1–10. PMID:10048088

502.   Gokaslan ST, Carlile B, Dudak M, Albores-Saavedra J (2001). Solitary cylindroma (dermal analog tumor) of the breast: a previously undescribed neoplasm at this site. Am J Surg Pathol. 25(6):823–6. PMID:11395563

503.   Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH (1994). Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 86(21):1600–8. PMID:7932824

504.   Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, et al.; BCFR; kConFab (2011). Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 13(4):R73. PMID:21787400

505.   Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 20(8):1319–29. PMID:19535820

506.   Goldstein NS, O’Malley BA (1997). Cancerization of small ectatic ducts of the breast by ductal carcinoma in situ cells with apocrine snouts: a lesion associated with tubular carcinoma. Am J Clin Pathol. 107(5):561–6. PMID:9128269

507.   Gong G, DeVries S, Chew KL, Cha I, Ljung BM, Waldman FM (2001). Genetic changes in paired atypical and usual ductal hyperplasia of the breast by comparative genomic hybridization. Clin Cancer Res. 7(8):2410–4. PMID:11489820

508.   Gonzalez CA, Riboli E (2010). Diet and cancer prevention: Contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer. 46(14):2555–62. PMID:20843485

509.   Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, et al. (2009). High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 46(10):689–93. PMID:19556618

510.   Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. (2009). Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 27(8):1250–6. PMID:19204208

511.   Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. (2011). Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 17(5):1082–9. PMID:21233401

512.   Goodman ZD, Taxy JB (1981). Fibroadenomas of the breast with prominent smooth muscle. Am J Surg Pathol. 5(1):99–101. PMID:7246853

513.   Gorlick R (2009). Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 152:467–78. PMID:20213409

514.   Górski B, Debniak T, Masojć B, Mierzejewski M, Medrek K, Cybulski C, et al. (2003). Germline 657del5 mutation in the NBS1 gene in breast cancer patients. Int J Cancer. 106(3):379–81. PMID:12845677

515.   Grabau D, Jensen MB, Rank F, Blichert-Toft M (2007). Axillary lymph node micrometastases in invasive breast cancer: national figures on incidence and overall survival. APMIS. 115(7):828–37. PMID:17614850

516.   Grady I, Gorsuch H, Wilburn-Bailey S (2008). Long-term outcome of benign fibroadenomas treated by ultrasound-guided percutaneous excision. Breast J. 14(3):275–8. PMID:18397185

517.   Granier G, Lemoine MC, Mares P, Pignodel C, Marty-Double C (2005). [Primary angiosarcoma of the male breast]. Ann Pathol. 25(3):235–9. PMID:16230950

518.   Green DM (1990). Mucoid carcinoma of the breast with choriocarcinoma in its metastases. Histopathology. 16(5):504–6. PMID:2163358

519.   Green I, McCormick B, Cranor M, Rosen PP (1997). A comparative study of pure tubular and tubulolobular carcinoma of the breast. Am J Surg Pathol. 21(6):653–7. PMID:9199642

519A.   Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature. 446(7132):153–8. PMID:17344846

520.   Gresik CM, Godellas C, Aranha GV, Rajan P, Shoup M (2010). Pseudoangiomatous stromal hyperplasia of the breast: a contemporary approach to its clinical and radiologic features and ideal management. Surgery. 148(4):752–7, discussion 757–8. PMID:20708765

520A.   Gruel N, Lucchesi C, Raynal V, Rodrigues MJ, Pierron G, Goudefroye R, et al. (2010). Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. Eur J Cancer. 46(13):2399–407. PMID:20570624

521.   Gu F, Schumacher FR, Canzian F, Allen NE, Albanes D, Berg CD, et al. (2010). Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev. 19(11):2877–87. PMID:20810604

522.   Gualco G, Weiss LM, Harrington WJ Jr, Bacchi CE (2009). Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome. Am J Surg Pathol. 33(12):1815–22. PMID:19816150

523.   Guérin M, Gabillot M, Mathieu MC, Travagli JP, Spielmann M, Andrieu N, et al. (1989). Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 43(2):201–8. PMID:2563719

524.   Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. (1998). E-cadherin germline mutations in familial gastric cancer. Nature. 392(6674):402–5. PMID:9537325

525.   Gump FE, Sternschein MJ, Wolff M (1981). Fibromatosis of the breast. Surg Gynecol Obstet. 153(1):57–60. PMID:7244975

526.   Günhan-Bilgen I, Oktay A (2007). Tubular carcinoma of the breast: mammographic, sonographic, clinical and pathologic findings. Eur J Radiol. 61(1):158–62. PMID:16987629

527.   Günhan-Bilgen I, Zekioglu O, Ustün EE, Memis A, Erhan Y (2002). Invasive micropapillary carcinoma of the breast: clinical, mammographic, and sonographic findings with histopathologic correlation. AJR Am J Roentgenol. 179(4):927–31. PMID:12239039

528.   Günther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schröder W, Tietze L (2001). Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol. 193(1):40–7. PMID:11169514

529.   Guo X, Chen L, Lang R, Fan Y, Zhang X, Fu L (2006). Invasive micropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis. Am J Clin Pathol. 126(5):740–6. PMID:17050071

530.   Guo X, Fan Y, Lang R, Gu F, Chen L, Cui L, et al. (2008). Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast. Mod Pathol. 21(9):1101–7. PMID:18469794

531.   Gylling AH, Nieminen TT, Abdel-Rahman WM, Nuorva K, Juhola M, Joensuu EI, et al. (2008). Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis. 29(7):1351–9. PMID:18550572

532.   Haagensen CD, editor. (1986). Diseases of the breast. 3rd ed. Philadelphia: Saunders.

533.   Haagensen CD, Lane N, Lattes R, Bodian C (1978). Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer. 42(2):737–69. PMID:209887

533A.   Hainaut P, Hollstein M (2000). p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 77:81–137. PMID:10549356

534.   Haj M, Weiss M, Loberant N, Cohen I (2003). Inflammatory pseudotumor of the breast: case report and literature review. Breast J. 9(5):423–5. PMID:12968967

535.   Hajdu M, Singer S, Maki RG, Schwartz GK, Keohan ML, Antonescu CR (2010). IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. J Pathol. 221(3):300–7. PMID:20527023

536.   Hajdu SI, Urban JA (1972). Cancers metastatic to the breast. Cancer. 29(6):1691–6. PMID:4337956

537.   Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. (1990). Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 250(4988):1684–9. PMID:2270482

537A.   Halpert B, Young MO (1948). Carcinosarcoma of the mammary gland. Surgery. 23(2):289–92. PMID:18901018

538.   Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW Jr, et al.; Collaborative Group on Hormonal Factors in Breast Cancer (2002). Alcohol, tobacco and breast cancer–collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 87(11):1234–45. PMID:12439712

539.   Hamele-Bena D, Cranor ML, Rosen PP (1996). Mammary mucocele-like lesions. Benign and malignant. Am J Surg Pathol. 20(9):1081–5. PMID:8764744

540.   Hamele-Bena D, Cranor ML, Sciotto C, Erlandson R, Rosen PP (1996). Uncommon presentation of mammary myofibroblastoma. Mod Pathol. 9(7):786–90. PMID:8832563